BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 19841408)

  • 1. Estimates of risk, empirical treatment observations, and unexpected laboratory findings reveal the complexity of nephrogenic systemic fibrosis.
    High WA
    Arch Dermatol; 2009 Oct; 145(10):1178-82. PubMed ID: 19841408
    [No Abstract]   [Full Text] [Related]  

  • 2. UV-A1 therapy for nephrogenic systemic fibrosis.
    Tran KT; Prather HB; Cockerell CJ; Jacobe H
    Arch Dermatol; 2009 Oct; 145(10):1170-4. PubMed ID: 19841406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of clonal T cells in the circulation of patients with nephrogenic systemic fibrosis.
    Kreuter A; Höxtermann S; Gambichler T; Tigges C; Hahn SA; Schieren G
    Arch Dermatol; 2009 Oct; 145(10):1164-9. PubMed ID: 19841405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid.
    Nazarian RM; Mandal RV; Kagan A; Kay J; Duncan LM
    J Am Acad Dermatol; 2011 Apr; 64(4):741-7. PubMed ID: 21414498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy.
    Foss C; Smith JK; Ortiz L; Hanevold C; Davis L
    Pediatr Dermatol; 2009; 26(5):579-82. PubMed ID: 19840315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors.
    Bahrami S; Raman SS; Sauk S; Salehmoghaddam S; Villablanca JP; Finn JP; Lu DS
    J Comput Assist Tomogr; 2009; 33(6):819-23. PubMed ID: 19940643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis: clinical picture and treatment.
    Marckmann P; Skov L
    Radiol Clin North Am; 2009 Sep; 47(5):833-40, vi. PubMed ID: 19744598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
    Jikki PN
    J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
    [No Abstract]   [Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.
    Weiss AS; Lucia MS; Teitelbaum I
    Nat Clin Pract Nephrol; 2007 Feb; 3(2):111-5. PubMed ID: 17251999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
    Wang SC
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
    [No Abstract]   [Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options.
    Schieren G; Wirtz N; Altmeyer P; Rump LC; Weiner SM; Kreuter A
    J Am Acad Dermatol; 2009 Nov; 61(5):868-74. PubMed ID: 19836645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
    van der Molen AJ
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):339-50. PubMed ID: 18811757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor.
    Lu CF; Hsiao CH; Tjiu JW
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157
    [No Abstract]   [Full Text] [Related]  

  • 20. Gadolinium and systemic fibrosis: guilt by association.
    Kay J; Czirják L
    Ann Rheum Dis; 2010 Nov; 69(11):1895-7. PubMed ID: 20959325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.